Table 2.
proUGn and UGn levels of tissues and plasma
| proUGn
|
UGn-like bioactivity
|
|||
|---|---|---|---|---|
| fmol/μg protein (n) | pmol/animal (n) | fmol/μg protein (n) | pmol/animal (n) | |
| Small intestine, proximal half | 12.6 ± 1.0 (21) | 1322 ± 160 (21) | ≤0.54 ± 0.16 (5)a | 56.8 ± 17 (5) |
| Small intestine, distal half | 10.0 ± 1.0 (17) | 978 ± 122 (21) | ||
| Small intestine, total | 11.3 ± 1.0 (21) | 2300 ± 262 (21) | ||
| Kidney | 2.1 ± 0.3 (12) | 247 ± 27 (6) | ||
| Colon | 1.1 ± 0.3 (5) | 27 ± 7 (5) | ||
| pmol/ml (n) | Estimated pmol/animalb (n) | pmol/ml (n) | ||
| Arterial plasma | 10.3 ± 1.7 (21) | Approximately 93 (21) | Not detectable (5) (<0.25)c | |
a
This represents an upper limit because a portion (∼20%) of the bioactivity is chromatographically distinct from authentic UGn.
b
Based on an estimated plasma volume of 9 ml for a typical 300-g animal.
c
This represents an upper limit, calculated on the basis of the detection limit of the assay.